Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 19/20 | 1.00 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.64 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15278119 | 1.00 | FOLH1 (1.00) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL17849539 | 0.96 | FOLH1 (0.92) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL18412142 | 0.92 | FOLH1 (0.85) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL19360024 | 0.91 | FOLH1 (0.83) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL20018424 | 0.91 | FOLH1 (0.83) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL29597774 | 0.90 | FOLH1 (0.82) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL10060822 | 0.90 | FOLH1 (0.81) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL13177561 | 0.90 | FOLH1 (0.81) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL30967340 | 0.89 | FOLH1 (0.80) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL29598755 | 0.89 | FOLH1 (0.80) | FOLH1RIMKLANAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023230729-A1 | SYNTHETIC ANTIGEN RECEPTORS FOR COVALENT IMMUNE RECRUITERS AND METHODS AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2023-12-07 | — | — | WO | disclosed |
| US-20230302164-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-09-28 | — | — | US | disclosed |
| US-20230173112-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-06-08 | — | — | US | disclosed |
| US-9371360-B2 | Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173112-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | PSMA1, PSMA2, FOLH1 | FOLH1 3/4885RIMKLA 1299/4885NAALAD2 198/4885 |
| US-20230302164-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | PSMA1, PSMA2, FOLH1 | FOLH1 3/4885RIMKLA 1290/4885NAALAD2 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.